{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-101971","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.581494+00:00","generated_at":"2026-05-17T21:29:16.735065+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH","bullets":["Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.","Initial term of 5 years with a 2-year automatic renewal; pricing based on per kg or per bottle.","Iterum Ireland provides rolling forecasts, with portion binding as firm orders; ACS to use commercially reasonable efforts for above-forecast orders.","Agreement includes customary IP protection, confidentiality, insurance, indemnification, and cGMP compliance obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-101971","json":"https://secwatch.observer/filing/0000950170-25-101971.json","markdown":"https://secwatch.observer/filing/0000950170-25-101971.md","text":"https://secwatch.observer/filing/0000950170-25-101971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025101971/0000950170-25-101971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025101971/itrm-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:29:16.735065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}